Protalix BioTherapeutics, Inc. (PLX)
Pre-Market:
| Previous Close | 1.2000 |
| Open | 1.1900 |
| Bid | 1.1400 x 800 |
| Ask | 1.2600 x 800 |
| Day's Range | 1.1700 - 1.2250 |
| 52 Week Range | 1.0900 - 3.5500 |
| Volume | |
| Avg. Volume | 351,662 |
| Market Cap | 88.393M |
| Beta (5Y Monthly) | 0.89 |
| PE Ratio (TTM) | 13.44 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Insider Monkey
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript March 14, 2024 Protalix BioTherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.07 EPS, expectations were $-0.03. Protalix BioTherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, […]
- GuruFocus.com
Protalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023
PLX Sees Regulatory Approvals and Commercial Progress Amidst Financial Growth
- Insider Monkey
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call Transcript
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call Transcript November 6, 2023 Protalix BioTherapeutics, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.07. Operator: Good morning, ladies and gentlemen. And welcome to the Protalix Biotherapeutics Third Quarter 2023 Financial and Business Results Conference Call. As a reminder, this conference is being recorded. I […]
